Terns Pharmaceuticals Inc (TERN)

$7.77 +0.27 (3.60%)
Market Cap 679.96M
Revenue (ttm) 0.00
Net Income (ttm) -88.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,843,200
Avg Vol 1,277,006
Day's Range N/A - N/A
Shares Out 87.51M
Stochastic %K 38%
Beta -0.03
Analysts Strong Sell
Price Target $15.83

Company Profile

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 525 5535
Fax: 650 275 4254
Address:
1065 East Hillsdale Boulevard, Suite 100, Foster City, United States
MoneyGroupLLC
MoneyGroupLLC Oct. 27 at 4:23 AM
Enter: $TERN Calls Strike Price: $8 Expiry Date: NOV 21 2025 Buy in Price: $1.10 - $4.90 Sell Price: $2.31 Profit : +110% (Turn every $1 into $2.10) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 26 at 8:35 AM
Enter: $TERN Calls Strike Price: $8 Expiry Date: NOV 21 2025 Buy in Price: $1.10 - $4.90 Sell Price: $2.31 Profit : +110% (Turn every $1 into $2.10) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 25 at 1:45 PM
Enter: $TERN Calls Strike Price: $8 Expiry Date: NOV 21 2025 Buy in Price: $1.10 - $4.90 Sell Price: $2.31 Profit : +110% (Turn every $1 into $2.10) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
NeverSellsAtTheRightTime
NeverSellsAtTheRightTime Oct. 24 at 1:35 PM
$TERN I would sell and rebuy after a short period. I like this long term, but there's tons of volatility after that bad data release.
2 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 24 at 12:01 PM
Enter: $TERN NOV 21 2025 $8 CALLS Buy in Price: $1.10 - $1.30 Take Profit: $2.37 Stop Bleeding: $0.97 ROI Potential: 115% https://moneygroup.us/
0 · Reply
FatMoneyScience
FatMoneyScience Oct. 23 at 10:20 PM
$TERN Starting to make a little more sense.
0 · Reply
HarryScrotmsRashy
HarryScrotmsRashy Oct. 23 at 9:58 PM
$TERN sold out today for a nice profit. This is a GOOD COMPANY. Will get back in if we get a nice pullback. GL to sll the longs in here.
2 · Reply
deadhandsignal
deadhandsignal Oct. 23 at 8:05 PM
$TERN 😉🩸
0 · Reply
HOSTILE
HOSTILE Oct. 23 at 4:59 PM
$TERN taking yesterday as a sign of strong demand Added more but ready to bail if it continues bleeding.
0 · Reply
MikeyNJ
MikeyNJ Oct. 23 at 4:30 PM
$TERN It's now a binary event on upcoming phase 1 data. Everyone knows the risk in these small biotechs. Place your bets.
0 · Reply
Latest News on TERN
Why Is Terns Pharmaceuticals Stock Trading Lower After Obesity Trial Data?

Oct 22, 2025, 2:43 PM EDT - 4 days ago

Why Is Terns Pharmaceuticals Stock Trading Lower After Obesity Trial Data?

Terns Pharma ends obesity drug program after mid-stage trial data

Oct 21, 2025, 4:56 PM EDT - 5 days ago

Terns Pharma ends obesity drug program after mid-stage trial data

Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity

Oct 21, 2025, 4:05 PM EDT - 5 days ago

Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Oct 2, 2025, 4:05 PM EDT - 24 days ago

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Terns Pharmaceuticals, Inc. (TERN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 12:13 PM EDT - 6 weeks ago

Terns Pharmaceuticals, Inc. (TERN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Terns Pharmaceuticals, Inc. - TERN-701 Investor Educational Webinar Transcript

Sep 3, 2025, 11:33 PM EDT - 7 weeks ago

Terns Pharmaceuticals, Inc. - TERN-701 Investor Educational Webinar Transcript

Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025

Aug 21, 2025, 4:05 PM EDT - 2 months ago

Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025

Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Aug 5, 2025, 4:05 PM EDT - 2 months ago

Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Terns Pharmaceuticals: A Risky Buy Ahead Of Q4 Obesity, Oncology Catalysts

Jul 11, 2025, 11:27 AM EDT - 3 months ago

Terns Pharmaceuticals: A Risky Buy Ahead Of Q4 Obesity, Oncology Catalysts

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions

Jun 23, 2025, 4:07 PM EDT - 4 months ago

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

May 29, 2025, 4:05 PM EDT - 5 months ago

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701

May 14, 2025, 9:30 AM EDT - 5 months ago

Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701

Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 8, 2025, 4:05 PM EDT - 6 months ago

Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference

Apr 30, 2025, 4:05 PM EDT - 6 months ago

Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference

Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Apr 2, 2025, 4:05 PM EDT - 7 months ago

Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

Mar 20, 2025, 4:05 PM EDT - 7 months ago

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)

Feb 26, 2025, 4:05 PM EST - 8 months ago

Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)

Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference

Feb 25, 2025, 8:05 AM EST - 8 months ago

Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference

Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer

Feb 24, 2025, 4:05 PM EST - 8 months ago

Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer

Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors

Feb 20, 2025, 4:05 PM EST - 8 months ago

Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors

Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 5, 2025, 4:05 PM EST - 9 months ago

Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

Feb 3, 2025, 4:05 PM EST - 9 months ago

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

Jan 8, 2025, 4:05 PM EST - 10 months ago

Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

Terns's stock soars as analysts cheer leukemia data — and predict more gains

Dec 4, 2024, 1:18 PM EST - 11 months ago

Terns's stock soars as analysts cheer leukemia data — and predict more gains

Terns Pharma broadens beyond obesity drugs with upbeat data in leukemia trial

Dec 3, 2024, 8:01 AM EST - 11 months ago

Terns Pharma broadens beyond obesity drugs with upbeat data in leukemia trial

Top 3 Health Care Stocks You'll Regret Missing In Q4

Nov 19, 2024, 7:52 AM EST - 1 year ago

Top 3 Health Care Stocks You'll Regret Missing In Q4

AMRN SLN

Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors

Nov 18, 2024, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors

RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.

Nov 15, 2024, 11:19 AM EST - 1 year ago

RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.

AMGN LLY NVO VKTX

Terns Pharmaceuticals: Obesity Advancement Continues With Other Q1 2025 Program Catalyst

Sep 25, 2024, 10:30 AM EDT - 1 year ago

Terns Pharmaceuticals: Obesity Advancement Continues With Other Q1 2025 Program Catalyst

Undercovered Stock Picks From September 6-12: Lithium, Uranium, Gold, & Plastic

Sep 13, 2024, 1:30 PM EDT - 1 year ago

Undercovered Stock Picks From September 6-12: Lithium, Uranium, Gold, & Plastic

ATLX BRZE DOCN EGO PL SLVM SMR

Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 12, 2024, 7:00 PM EDT - 1 year ago

Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Terns Announces Pricing of Upsized $150.15 Million Public Offering

Sep 10, 2024, 10:50 PM EDT - 1 year ago

Terns Announces Pricing of Upsized $150.15 Million Public Offering

Terns Pharmaceuticals: Weight Loss Drug TERN-601 Is Competitive

Sep 10, 2024, 10:25 AM EDT - 1 year ago

Terns Pharmaceuticals: Weight Loss Drug TERN-601 Is Competitive

Terns Announces Proposed Public Offering

Sep 9, 2024, 4:01 PM EDT - 1 year ago

Terns Announces Proposed Public Offering

Terns Pharmaceuticals Stock Is Soaring on Good Data for Weight-Loss Pill

Sep 9, 2024, 9:58 AM EDT - 1 year ago

Terns Pharmaceuticals Stock Is Soaring on Good Data for Weight-Loss Pill

Top 2 Health Care Stocks That May Collapse This Quarter

Sep 9, 2024, 9:12 AM EDT - 1 year ago

Top 2 Health Care Stocks That May Collapse This Quarter

IMVT

Terns Pharmaceuticals' stock soars 30% after biotech posts positive results in trial of weight-loss drug in pill form

Sep 9, 2024, 7:48 AM EDT - 1 year ago

Terns Pharmaceuticals' stock soars 30% after biotech posts positive results in trial of weight-loss drug in pill form

Terns Pharmaceuticals' oral obesity drug cuts weight by 4.9% in early study

Sep 9, 2024, 7:34 AM EDT - 1 year ago

Terns Pharmaceuticals' oral obesity drug cuts weight by 4.9% in early study

Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity

Sep 9, 2024, 7:05 AM EDT - 1 year ago

Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity

Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition

Jul 29, 2024, 4:05 PM EDT - 1 year ago

Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition

Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA's 84th Annual Scientific Sessions and Upcoming Conference Participation

Jun 21, 2024, 6:30 PM EDT - 1 year ago

Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA's 84th Annual Scientific Sessions and Upcoming Conference Participation

Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day

May 17, 2024, 4:05 PM EDT - 1 year ago

Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day

Mizuho still recommends Terns Pharma as a cheap entry to the weight-loss-drug craze

May 15, 2024, 12:33 PM EDT - 1 year ago

Mizuho still recommends Terns Pharma as a cheap entry to the weight-loss-drug craze

Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates

May 13, 2024, 8:05 AM EDT - 1 year ago

Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates

Terns Pharmaceuticals Announces Leadership Changes

May 8, 2024, 4:05 PM EDT - 1 year ago

Terns Pharmaceuticals Announces Leadership Changes

Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024

May 7, 2024, 4:05 PM EDT - 1 year ago

Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024

Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation

Apr 29, 2024, 4:05 PM EDT - 1 year ago

Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation

Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer

Apr 10, 2024, 4:05 PM EDT - 1 year ago

Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer

This small-cap stock is expected to take off — if its weight-loss pill trial succeeds

Mar 28, 2024, 3:02 PM EDT - 1 year ago

This small-cap stock is expected to take off — if its weight-loss pill trial succeeds

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates

Mar 14, 2024, 4:05 PM EDT - 1 year ago

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates

MoneyGroupLLC
MoneyGroupLLC Oct. 27 at 4:23 AM
Enter: $TERN Calls Strike Price: $8 Expiry Date: NOV 21 2025 Buy in Price: $1.10 - $4.90 Sell Price: $2.31 Profit : +110% (Turn every $1 into $2.10) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 26 at 8:35 AM
Enter: $TERN Calls Strike Price: $8 Expiry Date: NOV 21 2025 Buy in Price: $1.10 - $4.90 Sell Price: $2.31 Profit : +110% (Turn every $1 into $2.10) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 25 at 1:45 PM
Enter: $TERN Calls Strike Price: $8 Expiry Date: NOV 21 2025 Buy in Price: $1.10 - $4.90 Sell Price: $2.31 Profit : +110% (Turn every $1 into $2.10) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
NeverSellsAtTheRightTime
NeverSellsAtTheRightTime Oct. 24 at 1:35 PM
$TERN I would sell and rebuy after a short period. I like this long term, but there's tons of volatility after that bad data release.
2 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 24 at 12:01 PM
Enter: $TERN NOV 21 2025 $8 CALLS Buy in Price: $1.10 - $1.30 Take Profit: $2.37 Stop Bleeding: $0.97 ROI Potential: 115% https://moneygroup.us/
0 · Reply
FatMoneyScience
FatMoneyScience Oct. 23 at 10:20 PM
$TERN Starting to make a little more sense.
0 · Reply
HarryScrotmsRashy
HarryScrotmsRashy Oct. 23 at 9:58 PM
$TERN sold out today for a nice profit. This is a GOOD COMPANY. Will get back in if we get a nice pullback. GL to sll the longs in here.
2 · Reply
deadhandsignal
deadhandsignal Oct. 23 at 8:05 PM
$TERN 😉🩸
0 · Reply
HOSTILE
HOSTILE Oct. 23 at 4:59 PM
$TERN taking yesterday as a sign of strong demand Added more but ready to bail if it continues bleeding.
0 · Reply
MikeyNJ
MikeyNJ Oct. 23 at 4:30 PM
$TERN It's now a binary event on upcoming phase 1 data. Everyone knows the risk in these small biotechs. Place your bets.
0 · Reply
anachartanalyst
anachartanalyst Oct. 23 at 3:02 PM
$TERN https://anachart.com/wp-content/uploads/ana_temp/1761231746_soc-img.jpg
0 · Reply
OGLUCIDBULL
OGLUCIDBULL Oct. 23 at 2:58 PM
$TERN this was a good one! Been selling calls like clockwork.
0 · Reply
pablo4
pablo4 Oct. 23 at 2:17 PM
$TERN I don't own TERN now, but I'd bet my bottom dollar there's an offer that'll be coming along. This is accumulation after news that otherwise could have sunk TERN. I mean, think about it. You've all seen how trial failures and discontinued programs affect a bio's stock price. Would any of you have jumped to buy TERN right after the news at a "higher" price than before the news? You know the answer is "no." Nonetheless, the price is now higher. This is a reaction that occurs with good news. You can try to spin the news that most investors actually wanted the obesity trial to fail and that's why TERN is now so strong. IMO, that argument is absurd. Even arguing the burn rate will now slow doesn't explain this. But, IMO, there was a party in waiting should the trial fail who is interested in acquiring TERN.....someone who knew they could gain the company more easily. My guess is they wanted this CML program and see great promise there. JMO
1 · Reply
HarryScrotmsRashy
HarryScrotmsRashy Oct. 23 at 1:41 PM
$TERN Gobble up them cheap shares.
0 · Reply
DARKP00L
DARKP00L Oct. 23 at 1:35 PM
$TERN 09:14 on Oct. 23 2025 JMP Securities Maintains Market Outperform on Terns Pharma, Lowers Price Target to $15 #tradeideas
0 · Reply
JarvisFlow
JarvisFlow Oct. 23 at 1:14 PM
JMP Securities has updated their rating for Terns Pharma ( $TERN ) to Market Outperform with a price target of 15.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 23 at 11:51 AM
Enter: $TERN NOV 21 2025 $9 CALLS Buy in Price: $0.50 - $0.53 Take Profit: $1.07 Stop Bleeding: $0.44 ROI Potential: 114% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
Whales22
Whales22 Oct. 23 at 7:01 AM
$TERN $HCTI $GYRE $NBY How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI
0 · Reply
BioRich
BioRich Oct. 23 at 3:21 AM
$ALT Hey Dazed, should have kept that liquor. May have come in handy as $TERN climbed 21% since your post. Oh, and $ALT was down 2.6%. Means your EE Score is 23.6%. Ouch. Bit of irony is the one comment on your post was from my (not so secret) stalker @Turribull Cheers!
0 · Reply
BioRich
BioRich Oct. 23 at 3:02 AM
$ALT $TERN I love it when my biggest stalker tries to bash me and my picks, only to fall on their face... yet again. Thanks @Turribull for trying to get cute with $TERN. They successfully restructured and because they were HONEST (unlike ALT and their scrapped Obesity Program), WS responded positively. In a turn of beautiful fortune, $TERN proceeded to gain 28.1% from the time of your ill-advised bash attempt. Oh, and $ALT went down 2.5%. So that means your EE is 30.6% on your embarrassing post. *EE - Effective Embarrassment For those looking to make money and not just join bagholding misery cults... Follow/ Subscribe for more suggestions and perspective. Would love to hear yours. Let's make some money. Cheers!
0 · Reply
MrSpibz
MrSpibz Oct. 22 at 10:07 PM
$TERN Offering or Buyout or Rinse & Repeat next results
1 · Reply
HarryScrotmsRashy
HarryScrotmsRashy Oct. 22 at 9:01 PM
$TERN love the losers who show up out of no where to bash a stock they think will tank. What loser low lifes. They have no money so they get happy when they think someone who has money loses some. Pathetic losers.
1 · Reply